3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
68
Lung Neoplasms
18
Neoplasms
7
Neoplasm Metastasis
7
Melanoma
5
Carcinoma
5
Mesothelioma, Malignant
4
Colorectal Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Carcinoma, Transitional Cell
3
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Non-Squamous Non-small Cell Lung Cancer
2
Non-Small Cell Lung Cancer Metastatic
2
Non Small Cell Lung Carcinoma NSCLC
2
Mesothelioma
2
Endometrial Neoplasms
2
Brain Neoplasms
2
Advanced Solid Tumors
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Solitary Fibrous Tumor, Pleural
1
Salivary Gland Neoplasms
1
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
1
Resectable Non-small Cell Lung Cancer
1
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Non Small Cell Lung Cancer NSCLC
×
Pemetrexed
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA